| 2.76 0.229 (9.06%) | 04-26 15:56 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.13 | 1-year : | 4.96 |
| Resists | First : | 3.53 | Second : | 4.25 |
| Pivot price | 2.94  |
|||
| Supports | First : | 2.39 | Second : | 1.98 |
| MAs | MA(5) : | 2.56 |
MA(20) : | 3.14 |
| MA(100) : | 3.33 |
MA(250) : | 2.64 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 14.1 |
D(3) : | 9.1 |
| RSI | RSI(14): 39.3 |
|||
| 52-week | High : | 5.26 | Low : | 1.07 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ARMP ] has closed above bottom band by 39.1%. Bollinger Bands are 41.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.8 - 2.81 | 2.81 - 2.83 |
| Low: | 2.46 - 2.48 | 2.48 - 2.49 |
| Close: | 2.74 - 2.76 | 2.76 - 2.78 |
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Wed, 24 Apr 2024
Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference - The Globe and Mail
Tue, 16 Apr 2024
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 6.8% in March - MarketBeat
Fri, 12 Apr 2024
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading Down 1.8% - MarketBeat
Thu, 21 Mar 2024
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update - PR Newswire
Mon, 04 Mar 2024
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva - PR Newswire
Wed, 21 Feb 2024
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 36 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 69.5 (%) |
| Held by Institutions | 3.5 (%) |
| Shares Short | 91 (K) |
| Shares Short P.Month | 100 (K) |
| EPS | -1.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.35 |
| Profit Margin | 0 % |
| Operating Margin | -843.8 % |
| Return on Assets (ttm) | -25.4 % |
| Return on Equity (ttm) | -358.7 % |
| Qtrly Rev. Growth | -8.4 % |
| Gross Profit (p.s.) | -0.82 |
| Sales Per Share | 0.11 |
| EBITDA (p.s.) | -1.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -50 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -1.68 |
| PEG Ratio | 0 |
| Price to Book value | -8.12 |
| Price to Sales | 24.63 |
| Price to Cash Flow | -2.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|